Month: November 2020

Washington, November 21 An Indian-American scientist has discovered a potential strategy to prevent life-threatening inflammation, lung damage and organ failure in patients diagnosed with Covid-19. Published online in the journal Cell, the research coming from the lab of Dr Thirumala-Devi Kanneganti, an Indian-born researcher working at St Jude Children's Research Hospital in Tennessee, identified the drugs after discovering that the hyper-inflammatory immune response associated with Covid-19 leads to tissue damage and multi-organ failure in mice by triggering inflammatory cell death pathways. The researchers detailed how the inflammatory cell death signalling pathway worked, which led to potential therapies to disrupt the proc...

<!-- --> Indian-American doctor Thirumala-Devi Kanneganti finds possible treatment to prevent covid deaths Washington: An Indian-American doctor and scientist has discovered a potential strategy to prevent life-threatening inflammation, lung damage and organ failure in patients diagnosed with COVID-19. Published online in the journal Cell, the research coming from the lab of Dr Thirumala-Devi Kanneganti, an Indian-born researcher working at St. Jude Children's Research Hospital in Tennessee, identified the drugs after discovering that the hyperinflammatory immune response associated with COVID-19 leads to tissue damage and multi-organ failure in mice by triggering inflammatory cell death pathways. The researchers detailed how the inflammatory cell death signaling pathway worked,...

');$vidEndSlate.removeClass('video__end-slate--inactive').addClass('video__end-slate--active');}};CNN.autoPlayVideoExist = (CNN.autoPlayVideoExist === true) ? true : false;var configObj = {thumb: 'none',video: 'world/2020/11/19/peru-chinese-coronavirus-covid-19-vaccine-trial-galdos-pkg-intl-hnk-vpx.cnn',width: '100%',height: '100%',section: 'domestic',profile: 'expansion',network: 'cnn',markupId: 'large-media_0',adsection: 'const-article-carousel-pagetop',frameWidth: '100%',frameHeight: '100%',posterImageOverride: {"mini":{"width":220,"type":"jpg","uri":"//cdn.cnn.com/cnnnext/dam/assets/201119134307-peru-chinese-coronavirus-covid-19-vaccine-trial-galdos-pkg-intl-hnk-vpx-00025226-small-169.jpg","height":124},"xsmall":{"width":307,"type":"jpg","uri":"//cdn.cnn.com/cnnnext/dam/assets/201119...

About Press Copyright Contact us Creators Advertise Developers Terms Privacy Policy & Safety How YouTube works Test new features © 2020 Google LLC ...

The "cold chain" is just one of the challenges in distributing vaccines worldwide. There are plenty of others: decisions about priority populations and databases to keep track of who's received what vaccine, where and when. Additionally, different vaccines may have more or less efficacy with different population groups; and governments will need PR campaigns to persuade people that vaccines are safe. But the logistics of transporting and storing vaccines -- getting them from the factory gate to the patient's arm -- are critical. And as most vaccines are likely to require two doses, the whole chain needs must be repeated within weeks. The Pfizer-BioNTech vaccine needs to be kept at around -70 degrees Celsius (-94 degrees Fahrenheit) while it's transported. That's 50 degrees Celsius colder...